Robert V Gunderson JR
CIK 1302450 · last filed 2026-05-22
Robert V Gunderson JR is a corporate insider who has filed 22 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing shows the insider bought $84.8K of ANDG on May 22, 2026. Across all open-market trades the lifetime net is +$286.9K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $864.6K across reported positions. 13 SEC filings were submitted jointly with Innoviva, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ANDG price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
REDWOOD CITY, CA 94063
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ANDG | Director | 15,000 | $57.64 | $864.6K | $286.9K | 2 | 2026-05-22 |
| Theravance Biopharma, Inc. (TBPH) Delisted | Director | 78,940 | $17.03 | $1.34M | $0 | 7 | 2021-04-29 |
| Vitae Pharmaceuticals, Inc (VTAE) Delisted | Director | 0 | — | — | $0 | 5 | 2016-10-25 |
| Innoviva, Inc. (THRX) Delisted | Director | 89,873 | $4.06 | $364.9K | $0 | 8 | 2013-04-26 |
Holdings By Holder
| Symbol | Holder | Shares | Share of Total | Reported |
|---|---|---|---|---|
| TBPH | Direct | 68,093 | 86.3% | 2021-04-29 |
| By Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP | 10,847 | 13.7% | 2021-04-29 | |
| Total | 78,940 | |||
| VTAE | Direct | 0 | — | 2016-10-25 |
| G&H Partners See Footnote |
0 | — | 2016-10-25 | |
| Total | 0 | |||
| THRX | Direct | 84,164 | 93.6% | 2013-04-26 |
| By Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP | 5,709 | 6.4% | 2013-04-26 | |
| Total | 89,873 |
Recent Filings
22 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-22 | ANDG | Buy (P) | +2,367 | $84.8K | EDGAR |
| 2025-12-22 | ANDG | Buy (P) | +12,633 | $202.1K | EDGAR |
| 2021-04-29 | Theravance Biopharma, Inc. (TBPH) Delisted | Grant (A) | +9,828 | $0 | EDGAR |
| 2020-04-30 | Theravance Biopharma, Inc. (TBPH) Delisted | Grant (A) | +6,635 | $0 | EDGAR |
| 2019-05-02 | Theravance Biopharma, Inc. (TBPH) Delisted | Grant (A) | +8,385 | $0 | EDGAR |
| 2018-05-03 | Theravance Biopharma, Inc. (TBPH) Delisted | Grant (A) | +8,186 | $0 | EDGAR |
| 2017-05-18 | Theravance Biopharma, Inc. (TBPH) Delisted | Grant (A) | +6,000 | $0 | EDGAR |
| 2016-10-25 | Vitae Pharmaceuticals, Inc (VTAE) Delisted | Mixed | −26,832 | -$563.5K | EDGAR |
| 2016-05-27 | Vitae Pharmaceuticals, Inc (VTAE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-05-05 | Theravance Biopharma, Inc. (TBPH) Delisted | Grant (A) | +6,000 | $0 | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).